Dianna Lundberg

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

Andrea Iskenderian, Nan Liu, Qingwei Deng et al. · Skeletal Muscle · 2018 · 48 citations · Full text

Medicine, Cell Biology, Pharmacotherapy +16

VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy

Jennifer Bosco, Zhiwei Zhou, Sofie Gabriëls et al. · Molecular Therapy — Methods & Clinical Development · 2021 · 19 citations · Full text

Medicine, Molecular Medicine, Antibody Engineering +15

Structural characterization of the α-N-acetylglucosaminidase, a key enzyme in the pathogenesis of Sanfilippo syndrome B

Gabriel Birrane, Anne-Laure Dassier, Alla Romashko et al. · Journal of Structural Biology · 2019 · 18 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application

Chuan Shen, Andrea Iskenderian, Dianna Lundberg et al. · Journal of Pharmacology and Experimental Therapeutics · 2018 · 14 citations · Full text

Engineering, Biotechnology, Pharmaceutical Biotechnology +14

Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases

Paolo G.V. Martini, Lynette Cook, Scott Alderucci et al. · BMC Immunology · 2010 · 12 citations · Full text

Life Sciences, Immunology, Pathology +15